Zentalis Pharmaceuticals, Inc.
ZNTLAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 5, 2026 | Leerink Partners | $8.00(+217%) | $2.52 | TheFly | |
| Aug 7, 2026 | Morgan Stanley | $5.00(+17%) | $4.28 | TheFly | |
| May 22, 2026 | H.C. Wainwright | Andrew Fein | $10.00(+142%) | $4.14 | StreetInsider |
| Apr 10, 2026 | Guggenheim | $10.00(+63%) | $6.14 | TheFly | |
| Nov 11, 2025 | Leerink Partners | Andrew Berens | $2.00(+52%) | $1.32 | StreetInsider |
| Jun 18, 2024 | Jefferies | Akash Tewari | $6.00(+39%) | $4.30 | TheFly |
| Jun 18, 2024 | Morgan Stanley | Matthew Harrison | $8.00(+93%) | $4.14 | StreetInsider |
| Jun 18, 2024 | Stifel Nicolaus | Bradley Canino | $10.00(+86%) | $5.39 | TheFly |
| Jun 18, 2024 | Wedbush | Robert Driscoll | $4.00(-30%) | $5.70 | TheFly |
| May 7, 2024 | Stifel Nicolaus | Bradley Canino | $32.00(+157%) | $12.43 | StreetInsider |
| Nov 14, 2022 | Wedbush | $32.00(+42%) | $22.56 | Benzinga | |
| Nov 11, 2022 | Morgan Stanley | $55.00(+163%) | $20.90 | Benzinga | |
| Nov 11, 2022 | Guggenheim | $28.00(+31%) | $21.35 | Benzinga | |
| Aug 10, 2022 | Leerink Partners | $42.00(+38%) | $30.41 | Benzinga | |
| Aug 10, 2022 | H.C. Wainwright | $55.00(+81%) | $30.41 | Benzinga | |
| Jul 29, 2022 | Stifel Nicolaus | Bradley Canino | $70.00(+146%) | $28.50 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 19, 2026 |
| Guggenheim | maintain | Buy | Apr 10, 2026 |
| Guggenheim | maintain | Buy | Mar 27, 2026 |
| Morgan Stanley | maintain | Equal Weight | Nov 12, 2025 |
| Wells Fargo | maintain | Equal Weight | Aug 7, 2025 |
| Wedbush | maintain | Neutral | May 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2025 |
| Wedbush | maintain | Neutral | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2025 |
| Wells Fargo | maintain | Equal Weight | Jan 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 29, 2025 |
| UBS | maintain | Neutral | Jan 28, 2025 |
| Guggenheim | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| Oppenheimer | maintain | Outperform | Sep 16, 2024 |
| Wedbush | upgrade | Underperform →Neutral | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| UBS | downgrade | Buy →Neutral | Jun 20, 2024 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Jun 18, 2024 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Jun 18, 2024 |
| Stifel | maintain | Buy | Jun 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 18, 2024 |
| Oppenheimer | maintain | Outperform | Jun 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.59 | $-0.49 | — | — |
| May 12, 2026 | $-0.50 | $-0.49 | — | — |
| Mar 26, 2026 | $-0.49 | $-0.41 | — | — |
| Nov 10, 2025 | $-0.37 | $-0.49 | — | — |
| Aug 6, 2025 | $-0.37 | $-0.56 | — | — |
| May 14, 2025 | $-0.67 | $-0.67 | — | — |
| Mar 26, 2025 | $-0.66 | $-0.75 | $26.9M | — |
| Nov 12, 2024 | $-0.56 | $-0.92 | — | — |
News
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:
SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on November 2, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 136,000 shares of the Company's common stock to four (4) …
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical O…
Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday, Marketbeat.com reports. They presently have a $10.00 target price on the stock. HC Wainwright's target price points to a potential upside of 335.73% from the stock's previous close.
SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentation at the European Society for Medic…
Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Insider and Institutional Ownership 69.6% of Johnson
Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation and Earnings This table compares Redhill
Stock analysts at Leerink Partners started coverage on shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) in a report released on Monday, MarketBeat reports. The firm set an "outperform" rating and a $8.00 price target on the stock. Leerink Partners' target price points to a potential upside of 195.20% from the company's current price.
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company's common stock to three (3) n…
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) received a bullish initiation from William Blair on Tuesday, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib.
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,753,525 shares of the company's stock, valued at approximately $18,205,000. BlackRock Inc. owned approximately 5.27% of Zentalis Pharmaceuticals as
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company's common stock to four (4…
Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk.
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced that it has closed its previously announced underwritten public offering of 26,450,000 shares of its common stock, including 3,450,000 shares sold pursuant to…
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share. The total gross proceed…
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, pre…